# Safety and Immunogenicity of NVX-CoV2705

> **NCT07079670** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 676 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** NVX-CoV2705

## Key facts

- **NCT ID:** NCT07079670
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-09
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-06-16
- **Target enrollment:** 676 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079670, "Safety and Immunogenicity of NVX-CoV2705". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07079670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*